ArticleInfection and drug resistance2026
A QuantiFERON
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes mellitus (DM) is a well-established independent risk factor for tuberculosis (TB), and the prevalence of latent tuberculosis infection (LTBI) among patients with DM remains a critical public health concern. This study aims to investigate the prevalence and predictive factors of LTBI in patients with DM using the QuantiFERON Methods: A cross-sectional study was conducted involving 195 participants (96 with DM and 99 healthy controls) at Wenzhou Central Hospital between June and December 2023. LTBI was diagnosed using the QFT-PLUS test, and data on patient characteristics, laboratory findings and computed tomography scans were gathered. A predictive model was constructed through univariate and multivariate logistic regression analyses. Results: Among individuals with DM, 28 (29.2%) were identified as having LTBI compared with 16.2% in healthy controls. The final predictive model included age (>60 vs ≤60 years, odds ratio [OR]: 4.994, 95% CI: 1.583-17.610), gender (male vs female, OR: 26.886, 95% CI: 5.224-231.700), duration of diabetes (>10 vs ≤10 years, OR: 3.450, 95% CI: 1.000-13.240) and presence of hyperlipidaemia (yes vs no, OR: 10.637, 95% CI: 2.299-82.340) as significant factors, yielding an area under the curve of 0.847 (95% CI: 0.765-0.928). Conclusion: This QFT-PLUS-based predictive model, incorporating readily available clinical parameters, demonstrates potential clinical utility for LTBI risk stratification and targeted TB screening in patients with DM. Future multicentre external validation studies with larger sample sizes are warranted before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.